Skip to content

Effects of Dioscorea Yam Gruel on Blood Lipid Profiles in PCI Patients With Coronary Heart Disease

Effects of Dioscorea Yam Gruel on Blood Lipid Profiles in PCI Patients With Coronary Heart Disease: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07589036
Enrollment
72
Registered
2026-05-15
Start date
2024-01-10
Completion date
2025-03-15
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease (CHD), PCI

Keywords

Dioscorea yam gruel, Coronary heart disease, Percutaneous coronary intervention, PCI, Blood lipids, Dietary therapy

Brief summary

This randomized controlled trial investigated the effects of Dioscorea yam gruel on blood lipid levels in patients with coronary heart disease after percutaneous coronary intervention (PCI). A total of 72 eligible post-PCI patients were randomly assigned to the control group or the intervention group. Patients in the control group received standard post-procedural treatment and care. In addition to this standard regimen, those in the intervention group were provided with approximately 150 g of Dioscorea yam gruel daily as a partial dinner replacement for 12 consecutive weeks. Serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and body mass index (BMI) were measured at baseline, and at 8 weeks and 12 weeks of the intervention.

Detailed description

Background: Percutaneous coronary intervention (PCI) is an important revascularization strategy for coronary heart disease, but it cannot reverse the fundamental pathological process of atherosclerosis. Dyslipidemia is a core risk factor for disease progression. This study aimed to investigate the effects of Dioscorea yam gruel, a traditional Chinese dietary therapy, on blood lipid levels in patients after PCI. Methods (Brief Outline): Seventy-two post-PCI patients were randomized 1:1 to control (standard care) or intervention (standard care plus 150 g/day Dioscorea yam gruel for 12 weeks). Lipid profiles were assessed at baseline, 8 weeks, and 12 weeks. Body mass index (BMI) was measured at baseline and 12 weeks.

Interventions

Standard post-procedural treatment and care including weekly health education lectures (1 hour each) and routine outpatient follow-up every 4 weeks

DIETARY_SUPPLEMENTDioscorea Yam Gruel

In addition to receiving all standard post-PCI care (weekly health education lectures and routine 4-week follow-up), patients consumed approximately 150 g of Dioscorea yam gruel daily as a partial dinner replacement for 12 consecutive weeks

Sponsors

900th Hospital of PLA Joint Logistic Support Force
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

Participants and care providers were not blinded due to the nature of the dietary intervention. Outcome assessors and data analysts were blinded to group allocation throughout the trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Meeting the diagnostic criteria for coronary heart disease (2020 edition) * Undergoing percutaneous coronary intervention (PCI) * Aged between 18 and 75 years * Having been on a stable dose of statin therapy for at least 4 weeks prior to screening * Being in a stable clinical condition, conscious, providing informed consent, and participating voluntarily

Exclusion criteria

* Low-density lipoprotein cholesterol (LDL-C) level \< 70 mg/dL(\<1.81mmol/L) at screening * Complicating with other severe diseases or diseases that affect blood lipid levels, such as malignant tumors, acute cerebrovascular disease, nephrotic syndrome, severe liver disease, Cushing's syndrome, and others * Pregnancy or lactation * Concurrently participating in other dietary or exercise intervention programs

Design outcomes

Primary

MeasureTime frameDescription
Blood Lipid ProfileBaseline, Week 8, Week 12Serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C) were measured at baseline, 8 weeks, and 12 weeks of the intervention

Secondary

MeasureTime frameDescription
Body Mass Index (BMI)Baseline, Week 12Body mass index was measured at baseline and at 12 weeks post-intervention. Height and weight were measured using a standard stadiometer and scale. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m\^2)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026